Jazz Pharmaceuticals plc (JAZZ) AI Stock Analysis

Jazz Pharmaceuticals plc is a biopharmaceutical company specializing in neuroscience and oncology therapies for unmet medical needs across the United States, Europe, and globally. Its commercial portfolio features treatments for sleep disorders and cancer, including Xyrem and Sunosi for narcolepsy and excessive daytime sleepiness, Erwinaze for acute lymphoblastic leukemia, Defitelio for hepatic veno-occlusive disease, Vyxeos liposome for therapy-related acute myeloid leukemia, and Zepzelca for metastatic small cell lung cancer. The company is advancing pipeline candidates including Xywav and JZP-324 for narcolepsy, JZP385 for essential tremor, JZP458 for pediatric and adult cancer therapy, and JZP150 for post-traumatic stress disorder.

Jazz Pharmaceuticals increased revenue from $3.09B in FY2021 to $4.27B in FY2025, recording a 5-year revenue CAGR of 12.5%. Annual revenue growth moderated from 30.9% in FY2021 and 18.3% in FY2022 to 4.9% in FY2025. Gross margin has remained elevated, reaching 88.2% in FY2025. Operating margin was 5.3% in FY2025 compared to 17.6% in FY2024, resulting in a net loss of -$356.1M. Over the trailing twelve months, revenue totaled $4.60B with an operating margin of 26.9% and a profit margin of 20.4%. In the latest quarter ending June 30, 2026, quarterly revenue grew 15.5% year-over-year, while quarterly earnings increased 3.2%.

As of June 30, 2026, Jazz Pharmaceuticals held $2.20B in cash and short-term investments alongside total debt of $4.41B, resulting in net debt of $2.21B. Total assets stood at $11.08B and shareholders' equity reached $4.80B, supporting a current ratio of 1.78 and a debt-to-equity ratio of 0.92. During FY2025, operating cash flow reached $1.36B and free cash flow was $1.15B. Capital allocation for FY2025 included $209.8M in capital expenditures and $125.0M in share buybacks.

JAZZ closed at $210.23 on October 16, 2026, trading at a trailing P/E of 14.4x and a forward P/E of 10.9x. Both valuation multiples sit below the median of its US-listed Healthcare peers, which have a trailing P/E of 24.6x and a forward P/E of 17.3x. The stock carries an EV/EBITDA of 11.0x versus the peer median of 12.0x, and a price-to-sales ratio of 3.0x compared to 4.1x. Over the past year, JAZZ gained 56.6%, outperforming the S&P 500 (SPY) return of 16.8%, although its 5-year return of 49.4% trailed the index's 83.0%.

Wall Street analysts hold 13 Strong Buy, 7 Buy, and 2 Hold ratings on JAZZ, with zero Sell or Strong Sell ratings. The mean price target is $294.64, representing a 40.1% upside against the last close of $210.23. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $4.72B and EPS of $21.12, reflecting expected EPS growth of 152.0%. For the following fiscal year, 19 analysts estimate revenue of $4.99B and EPS of $26.05. The company beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of Jazz Pharmaceuticals plc (JAZZ). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: JAZZ income statement, JAZZ balance sheet, JAZZ key metrics, JAZZ analyst forecast, JAZZ chart. See the JAZZ stock overview for the latest quote and news.